本帖最后由 老马 于 2012-1-13 21:20 编辑
! J$ Y; c; { h+ q0 ?
7 G$ n7 b' f" h$ P- m: d爱必妥和阿瓦斯丁的比较
- t. X8 C3 d( p' u
9 P: V9 x* k8 |) U9 D5 _' U1 D2 K) Qhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/0 `8 P/ ?2 Y Z9 R5 v* ]
# j7 I" B& ?* m& D7 N6 D! R# U
4 S* G9 L) ?" @; z
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
$ {1 {& z/ f$ i: r# H5 z==================================================+ N' J* D9 y0 K% y3 L Q
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
# n) J4 d. ^. B/ {- xPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
- e% u+ z) y2 g0 n7 u! F( DResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
8 ?+ F) z4 [+ p7 k" j9 Q* C
|